Tempo Acquires ALM Works to Deliver Integrated Strategic Portfolio Management Offering
22.12.2021 20:17:00 EET | Business Wire | Press release
Tempo Software, the leader in team time management and productivity-enhancing solutions, today announced the acquisition of ALM Works, developer of the Structure for Jira software suite that enables project and program managers to make better decisions, work more efficiently, and deliver predictable results. A top-selling project management solution, ALM Works helps over 5000 organizations worldwide visualize, track and manage progress across large-scale, complex projects. Tempo and ALM Works together will provide the first suite of purpose-built program management apps to meet project, program and portfolio management needs for over 70 million users within the Atlassian Ecosystem.
The combination of Tempo’s team time and capacity management solutions and ALM Works’ project and artifact structuring solutions will enable program managers to easily understand whether key initiatives are on track and meeting strategic objectives. A recent Tempo survey showed that 55% of software development executives reported that they use time tracking insights to inform project and portfolio management. This new combination of Tempo and ALM Works will provide organizations with the visibility required to move between strategy and daily execution, make informed decisions, and share progress with executives and stakeholders.
“For over a decade, ALM Works has set themselves apart within the Atlassian Ecosystem due to their focused efforts on helping bring structure to complex project data,” said Mark Lorion, CEO, Tempo Software. “Through an even tighter integration with ALM Works, we are excited to bring a modern, easy-to-use and scalable program management solution to market and to our many shared customers and partners. Together we will uniquely support the teams who operate within Jira on a daily basis and provide the data that senior leadership teams need to be responsive as they set product strategy for an organization.”
“ALM Works focuses on enabling project and program managers to solve complex problems with our flexible, adaptable Structure solution,” said Igor Sereda, ALM Works CEO. “By bringing ALM Works together with Tempo’s industry-leading time tracking and productivity management suite of products, we’re now well-positioned to deliver the most comprehensive program and portfolio management offering to the market. I am proud of the work our team has accomplished over the past 17 years and look forward to bringing visibility and strategic insights to even more people and teams.”
Combined with the recent acquisition of Roadmunk, the addition of ALM Works strengthens Tempo’s strategic portfolio management offering. As a modern and integrated solution suite, Tempo will meet the growing needs of today’s distributed and complex product organizations who need to project, plan, and adapt based on timely organizational capacity data and insights.
Supporting Resources:
- ALM Works website: https://almworks.com/
- Tempo website: https://www.tempo.io
- ALM Works blog: https://almworks.com/blog.html
- Tempo blog: https://www.tempo.io/blog
About Tempo
Tempo Software offers integrated applications for time management, resource planning, and budget management for software engineering and product management teams. Our customers gain an unrivaled understanding of time and effort, and they improve how their teams plan and manage their work. This provides an aligned understanding of and plan for how time –the most precious, and finite resource–is optimized. Tempo Software is seamlessly integrated across popular DevOps tools and a natural and automated part of users’ workflows.
Headquartered in Boston and with offices in Reykjavik, Iceland and Montreal, Canada, Tempo Software is one of the largest and most successful companies in the Atlassian ecosystem.
Tempo has more than 20,000 customers across a range of industries in more than 100 countries. It works with hundreds of partners around the world, offering resale, training, and consultancy in local languages. Tempo is available in English, French, German, Spanish, Portuguese, and Russian, with Japanese coming soon. To learn more about Tempo, visit www.tempo.io
About ALM Works
ALM Works provides software products to empower project managers around the world with visibility and control. ALM Works’ flagship product, Structure for Jira, is a project and portfolio management tool for Atlassian, used by thousands of customers in over 100 countries. Structure, together with its extensions such as Structure.Gantt, is made for project managers and other people responsible for planning, tracking, and getting things done at an organization. It allows them to work efficiently, deliver predictable results, see problems earlier, make better decisions and communicate with clarity and confidence to their teams, managers and clients.
ALM Works is headquartered in Boston with offices in Saint-Petersburg, Russia. To learn more about ALM Works, visit almworks.com.
About Diversis Capital, L.P.
Founded in 2013, Diversis is a software and technology focused private equity fund with $1bn+ in AUM that invests in lower middle-market companies, targeting situations where it can add unique value in helping a company reach the next level. With a collaborative approach to investing, its Operating Partners and Strategic Advisors work alongside management teams to help build successful organizations positioned for long-term growth. To learn more, visit www.diversis.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211222005442/en/
Contact information
Escalate PR for Tempo.io
tempo@escalatepr.com
Joel Richman
joel@escalatepr.com
+1 617 312 5942
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
